Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9CV4P)

Drug Name

Sant7 Drug Info

Synonyms

beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Investigative	[1]

Cross-matching ID

PubChem CID: 128225
CAS Number: CAS 102977-57-1
TTD Drug ID: DM9CV4P

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tocilizumab	DM7J6OR	Giant cell arteritis	4A44.2	Approved	[2]
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[3]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[4]
SAR153191	DMXAO4J	Ankylosing spondylitis	FA92.0	Phase 3	[5]
SA-237	DM7F2VG	Encephalopathy	8E47	Phase 3	[6]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[7]
ALX-0061	DMO1VHC	Autoimmune diabetes	5A10	Phase 2	[8]
SBP-002	DM9F7R0	Melanoma	2C30	Terminated	[3]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[9]
FM-101	DMXK6EI	Multiple myeloma	2A83	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 6 receptor (IL6R)	TT0E5SK	IL6RA_HUMAN; IL6RB_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
2	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
5	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6	IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
7	Clinical pipeline report, company report or official report of Ablynx.
8	The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
9	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.